esanex

INDIANAPOLIS, IN

Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.

Other investors include: Intersouth Partners, Esanex Holdings LTD, and the Indiana Seed Fund.